Year Founded
2016
Ownership
Private
Employees
~50
Therapeutic Areas
Oncology
Stage
Phase 1
Modalities
CAR T cell therapy (CAR-T)

AffyImmune Therapeutics General Information

AffyImmune's lead candidate, AIC100, has shown promising results, including a confirmed complete response in a patient with anaplastic thyroid cancer. The company has also received FDA RMAT designation for AIC100.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Natick, Massachusetts
United States

Drug Pipeline

AIC100
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to AffyImmune Therapeutics's pipeline data

Book a demo

Key Partnerships

No partnerships listed

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

AffyImmune Therapeutics Funding

Deal TypeDateAmountStatusStage
Later Stage VCOct 7, 2021$20.0MCompletedPhase 1
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view AffyImmune Therapeutics's complete valuation and funding history, request access »

AffyImmune Therapeutics Investors

Northpond Ventures
Investor Type: Venture Capital
Holding: Minority